Humulin N (Insulin Human (Rdna))

Humulin N is a recombinant human insulin (rDNA) supplied as a solution for injection. It is provided in the standard concentration for subcutaneous use and is marketed in the European Union as a prescription‑only antidiabetic agent. Humulin N is indicated for basal insulin therapy in both type 1 and type 2 diabetes, helping to maintain steady glucose levels between meals and overnight. It is supplied in single‑dose vials for convenient administration.

Humulin N is used as a basal (long‑acting) insulin to control blood glucose in diabetes.

- Type 1 diabetes mellitus as part of a basal‑bolus regimen. - Type 2 diabetes mellitus when oral agents are insufficient. - Adjunct therapy for patients requiring stable overnight glucose control. - Combination with rapid‑acting insulin for full‑day coverage. - May be used during pregnancy only under specialist supervision if indicated.

Like other insulin preparations, Humulin N may cause injection‑site reactions and systemic effects related to hypoglycemia.

Common: - Low blood sugar (hypoglycemia) presenting as sweating, tremor, or confusion. - Redness, swelling, or itching at the injection site. - Weight gain associated with improved glucose utilization. - Lipodystrophy (localized fat accumulation or loss) at repeated injection sites. - Bruising or bleeding at injection site.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Persistent hyperglycemia indicating possible insulin resistance or dosing error. - Hypokalemia secondary to insulin‑driven cellular uptake of potassium. - Anaphylactic shock requiring immediate medical attention.

Before initiating Humulin N, clinicians should evaluate patient history and monitor several clinical parameters to reduce risk.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Review history of hypoglycemia unawareness or severe episodes. - Adjust dose when starting or stopping concomitant glucocorticoids, beta‑blockers, or diuretics. - Educate patients on proper injection technique and rotation of sites. - Advise regular blood glucose monitoring, especially during illness or changes in diet. - Consider pregnancy status; insulin is the preferred agent but requires specialist guidance.

Humulin N can interact with several medications that affect glucose metabolism or insulin pharmacodynamics.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment, which may cause severe hypoglycemia. - MAO‑B inhibitors (e.g., selegiline) that potentiate insulin’s glucose‑lowering effect. - High‑dose salicylates that may increase insulin sensitivity and risk of hypoglycemia.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Corticosteroids, which can raise blood glucose and require higher insulin doses. - Thiazide diuretics, which may increase serum potassium shifts and affect glucose control.